One of the most recent high-profile Cancer Prevention and Research Institute of Texas awards has gone to UTMB, which will receive more than $3.2 million in new funding to continue research efforts to collect comprehensive data relating to population research on cancer treatments and outcomes in Texas. The grant comes as part of a larger collection of research grants awarded to a host of top Texas-based research institutions that will give them the necessary funding to continue previously CPRIT-funded cancer research. The ongoing study spearheaded by UTMB is titled the “Comparative Effectiveness Research on Cancer in Texas,” and will be able to continue for the next two years. The study, which is headed by Dr. James Goodwin, vice president and chief research officer at UTMB, also includes researchers from MD Anderson, Rice University and the Texas Cancer Registry, in addition to a team of UTMB researchers supporting Goodwin’s efforts. Over the next two years, the consortium of researchers will continue their look into how breast, colon, and prostate cancer screening is administered throughout Texas — specifically emphasizing any correlation between patient outcomes and patients’ access to varying quality levels of cancer treatment care. The news also appears in BioPortfolio, the Bay Area Citizen and